ARB + diuretic
Take control with a
Powerful ARB + diuretic
EDARBYCLOR® (azilsartan medoxomil/chlorthalidone) is 2 medicines in 1 to help you get to goal. If you’re on 2 or more medications and still short of your blood pressure goal, EDARBYCLOR may be a good fit for you.1
EDARBYCLOR combines the same active ingredient in EDARBI®, azilsartan medoxomil, with the diuretic (“water pill”) chlorthalidone. (In fact, it’s the only fixed dose combination drug available with chlorthalidone.)2 The ARB in EDARBYCLOR works by relaxing blood vessels, and the diuretic works in the kidneys to help flush excess water and salt (sodium) from the body. Together, these 2 medicines help to lower blood pressure.2
I’m not just 169/96.
Medication in Studies.1*
When scientists compared EDARBYCLOR 40/25 mg with Benicar HCT® (olmesartan medoxomil-hydrochlorothiazide) 40/25 mg for 12 weeks, they found that EDARBYCLOR lowered blood pressure better.1
14.5% greater reduction
than Benicar HCT
This is important because millimeters matter.
Even a reduction of 2 to 5 mm Hg in your systolic blood pressure may lower your cardiovascular risk.3,4,†
Proper medical treatment and control has been shown to lower the risk of dying from heart-related problems such as heart attack and stroke.3,4†
*Based on clinical trial data vs Benicar HCT® (olmesartan medoxomil-hydrochlorothiazide).1
† CV risk reduction with EDARBI and EDARBYCLOR has not been established.
This randomized, double-blind, forced-titration clinical trial compared the efficacy and safety of EDARBYCLOR with those of another ARB/diuretic combination, olmesartan medoxomil-hydrochlorothiazide (Benicar HCT). The study’s 1,071 patients were selected based on systolic blood pressure (SBP) between 160 and 190 mm Hg measured at a clinic in a seated position. The study’s primary measurement was the change in each patient’s starting blood pressure compared with his/her SBP measured in the clinic at week 12.1 Read more about this study design and results at www.edarbi.com/hcp.
African American Patients4,5
From a subgroup analysis of the same clinical trial, another benefit of EDARBYCLOR was discovered: It is especially effective at lowering blood pressure among African American patients with high blood pressure. 4,5
18% greater SBP reduction
than Benicar HCT5*
This is important because common treatments such as renin angiotensin system (RAS) inhibitors are generally less effective in low-renin populations, including African Americans.6 EDARBYCLOR provides a choice for these populations.5
*Based on clinical trial data vs Benicar HCT, comparing 40/25 dose of EDARBYCLOR to 40/25 mg dose of Benicar HCT among African American participants.5
This randomized, double-blind, forced-titration clinical trial compared the efficacy and safety of EDARBYCLOR with those of another ARB/diuretic combination, olmesartan medoxomil-hydrochlorothiazide (Benicar HCT). The study’s 1,071 patients were selected based on systolic blood pressure (SBP) between 160 and 190 mm Hg measured at a clinic in a seated position. The study’s primary measurement was the change in each patient’s starting blood pressure compared with his/her SBP measured in the clinic at week 12.1
Based on this post hoc subgroup analysis, EDARBYCLOR 40/25 mg delivered statistically superior clinic SBP reduction in self-identified African American patients with hypertension versus Benicar HCT 40/25 mg at week 12.5
This is a subgroup analysis. The study was not powered to detect a difference in these subgroups; therefore, the ability to interpret the P value as significant is reduced.5
Read more about this study design and results at www.edarbi.com/hcp.
Clinical studies of more than 3,900 people taking EDARBYCLOR found that side effects of the medication were generally mild and transient in nature:
Your doctor may monitor the potassium and creatinine levels in your blood while you’re taking EDARBYCLOR.2
EDARBYCLOR may cause serious side effects, including low blood pressure (hypotension), which may cause dizziness or feeling faint.
Vomiting and diarrhea, a low-salt diet, sweating a lot, or not drinking enough fluids can also lead to low blood pressure.7
If you are taking EDARBYCLOR and experience side effects that concern you, call your doctor for medical advice. You are encouraged to report side effects of prescription drugs to Azurity/Arbor Pharmaceuticals, LLC Medical Information at 1-866-516-4950 or to the FDA at www.fda.gov/medwatch or call 1-800-FDA-1088.
EDARBYCLOR is a once-daily oral medication that can help you achieve your blood pressure goals.2
- May be administered with or without food.
- May be administered with other antihypertensive agents.
- Dose may be increased to 40/25 mg after 2 to 4 weeks as needed to achieve BP goals.
- Correct volume depletion in patients prior to use.
- Doses above maximum are probably not useful.
Take control with a powerful ARB8
1. Cushman WC, Bakris GL, White WB, et al. Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension. Hypertension. 2012;60(2):310-318.
2. Edarbyclor [package insert]. Atlanta, GA: Azurity/Arbor Pharmaceuticals, LLC; .
3. Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics-2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139-e596. doi:10.1161/CIR.0000000000000757
4. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):1269-1324.
5. Ferdinand KC, Bakris GL, Cushman WC, et al. Comparison of effectiveness of azilsartan medoxomil and olmesartan in Blacks versus whites with systemic hypertension. Am J Cardiol. 2018;122(9):1496-1505.
6. Williams SF, Nicholas SB, Vaziri ND, Norris KC. African Americans, hypertension and the renin angiotensin system. World J Cardiol. 2014;6(9):878-889. doi:10.4330/wjc.v6.i9.878
7. Low blood pressure — when blood pressure is too low. American Heart Association. Updated October 23, 2016. Accessed December 17, 2021. https://www.heart.org/en/health-topics/high-blood-pressure/the-facts-about-high-blood-pressure/low-blood-pressure-when-blood-pressure-is-too-low
8. White WB, Weber MA, Sica D, et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension. 2011;57(3):413-420. doi:10.1161/HYPERTENSIONAHA.110.163402
9. Edarbi [package insert]. Atlanta, GA: Azurity/Arbor Pharmaceuticals, LLC; .